Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 374

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 374
---
 extent we determine that such action
does not materially and adversely affect the value of an award or that such action is in the best interest of the affected participant
or any other person as may then have an interest in the award.

68

The
Administrator can cause a participant to forfeit any award, and require the participant to disgorge any gains attributable to the award,
if the participant engages in any action constituting, as determined by the Administrator in its discretion, cause for termination, or
a breach of a material company policy, any award agreement or any other agreement between the participant and us or one of our affiliates
concerning noncompetition, nonsolicitation, confidentiality, trade secrets, intellectual property, nondisparagement or similar obligations.

Any
awards granted under the 2023 Omnibus Plan, and any shares of common stock issued or cash paid under an award, will be subject to any
recoupment under our Compensation Recovery Policy (as described below), or any recoupment or similar requirement otherwise made applicable
by law, regulation or listing standards to us or that may be provided for in any cash or equity award granted by us.

Compensation
Recovery Policy

On
October 2, 2023, our Board of Directors adopted a policy (commonly known as a “clawback” policy) which provides for the recovery
of erroneously awarded incentive compensation to certain of our officers in the event that we are required to prepare an accounting restatement
due to material noncompliance by us with any financial reporting requirements under the federal securities laws. This policy is designed
to comply with Section 10D of the Securities Exchange Act of 1934, as amended, related rules and the listing standards of the Nasdaq
Stock Market or any other securities exchange on which our shares are listed in the future. The policy is administered by our Board of
Directors or, if so designated by the Board of Directors, the Compensation Committee. Any determinations made by the Board shall be final
and binding on all affected individuals.

The
individuals covered by this policy (the “Covered Officers”) are any current or former employee who is or was identified as
our president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller),
any vice-president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other
officer who performs a significant policy-making function, or any